A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

The end point of this double-blind ... 1999;82(suppl 4):IV14 IV22. Altered adrenergic receptor sensitivity due to polymorphic variation. Arg389=arginine; Gly389=glycine. Adapted from J Biol ...

Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid​ medications like Vicodin and OxyContin.

Rock musician Mike Peters says it's been an 'intense' time preparing for immune therapy treatment.

The receptor fold is very similar to that of rhodopsin ... such as those in the highly conserved D/ERY motif at the cytoplasmic end of transmembrane helix 3 or those in transmembrane helix 6 ...

Somewhere in writing The Power Fantasy, an original Image Comics series with artist Caspar Wijngaard ( Home Sick Pilots, ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...